已发表论文

新型含氮杂环化合物的计算机辅助药物设计及其对胶质瘤 U251 细胞和乳腺癌 MCF-7 细胞的抑制作用

 

Authors Qian L, Zhu Y

Received 14 March 2018

Accepted for publication 1 May 2018

Published 27 June 2018 Volume 2018:12 Pages 1931—1939

DOI https://doi.org/10.2147/DDDT.S168130

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 6

Editor who approved publication: Dr Anastasios Lymperopoulos

Background: Glioma and breast cancer are severe malignant cancerous tumors that highlight the importance of developing new anti-cancer drugs. The aim of this study was to explore the effects of a novel nitrogenous heterocyclic compound on glioma and breast cancer cells and to determine its mechanism of action. 
Methods: We designed and synthesized a novel nitrogenous heterocyclic compound, 3-(4-amino-1H-benzo[d]imidazole-2-carboxamido)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, based on alkylglycerone phosphate synthase (AGPS) using computer-aided drug design (CADD), and we measured its effect on the proliferation, invasion, cell cycle and apoptosis of U251 glioma and MCF-7 breast cancer cells. In addition, the compound’s effect on the expression of tumor-related mRNA, circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) was explored. 
Results: It was found that the nitrogenous heterocyclic compound could induce cell cycle arrest at the G2/M phase of U251/MCF-7 cells and activate apoptosis. Real-time PCR showed that the expression levels of tumor-related mRNA, circRNAs and lncRNAs were impacted. 
Conclusion: We concluded that the nitrogenous heterocyclic compound inhibits the proliferation and invasion of U251 glioma and MCF-7 breast cancer cells through the induction of apoptosis and cell cycle arrest by regulating tumor-related genes.
Keywords: nitrogenous heterocyclic compound, glioma, breast cancer, proliferation, invasion




Figure 2 The design of the nitrogenous heterocyclic compound and...